Nippon India Pharma Bonus Bonus Growth Direct Plan
SIP amount
Temporarily restricted by fund house
Lumpsum amount
Temporarily restricted by fund house

Nippon India Pharma Bonus Bonus Growth Direct Plan

NAV
₹560.9325
+1.14%
(22 Nov)
AUM
8,689 Cr
TER
0.91%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Asset Under Management (AUM) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+54.0%
+54.0%
+54.0%
+44.6%
+36.5%
3Y
+36.5%
+36.5%
+36.5%
+34.9%
+20.6%
5Y
+25.4%
+25.4%
+25.4%
NA
+28.6%
ALL
+12.5%
+12.5%
+12.5%
+28.8%
+19.2%
VOL
20.3%
20.3%
20.3%
23.1%
15.6%
TER
0.8%
0.8%
0.8%
0.5%
0.9%
AUM
₹4,471 Cr
₹4,471 Cr
₹4,471 Cr
₹5,456 Cr
₹8,689 Cr
INFO
0.61
0.61
0.61
1.25
1.23
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Nippon India Pharma Bonus Bonus (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Aug
Top holdings
Sun Pharmaceuticals Industries Ltd
13.8%
Lupin Ltd
8.3%
Divi's Laboratories Ltd
8.0%
Cipla Ltd
5.9%
Dr Reddy's Laboratories Ltd
5.7%
Apollo Hospitals Enterprise Ltd
5.2%
Ajanta Pharma Ltd
3.6%
Vijaya Diagnostic Centre Ltd
3.2%
Gland Pharma Ltd
3.2%
Aurobindo Pharma Ltd
3.1%
Top industry exposure
Healthcare
96.5%
Other information
Minimum SIP
Restricted (AMC)
Minimum lumpsum
Restricted (AMC)
Additional lumpsum
Restricted (AMC)
Portfolio turnover
14%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.
Fund manager(s)
Sailesh Raj Bhan
Kinjal Desai

FAQs